Sandbox 123456: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
heme cofactor green link |
||
| Line 1: | Line 1: | ||
<Structure load='5FSA' size='350' frame='true' align='right' caption='Crystal structure of sterol 14-alpha demethylase (CYP51) from a pathogenic yeast Candida albicans in complex with the antifungal drug posaconazole' /> | <Structure load='5FSA' size='350' frame='true' align='right' caption='Crystal structure of sterol 14-alpha demethylase (CYP51) from a pathogenic yeast Candida albicans in complex with the antifungal drug posaconazole' /> | ||
==Introduction== | ==Introduction== | ||
| Line 11: | Line 10: | ||
*IUPAC name: 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one | *IUPAC name: 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one | ||
The primary component of Noxafil, posaconazole (green link) is a potent, broad-spectrum antifungal drug. It was derived from a similar triazole antifungal agent, Itraconazole. The differences in structure are that the chlorine substituents in the aromatic ring on the left-hand side of the images are replaces with fluorines (green link) and that the triazolone sidechain is hydroxylated in the posaconazole structure<ref>PMID: 21059682 </ref>. The extended side chain residues and hydrophobic contacts enhances antifungal activity by allowing tighter binding affinities to the heme cofactor in the active site of CYP450-dependent enzyme lanosterol alpha-demthylase (CYP51) (Groll)(academic.oup.com). The tighter binding affinity of posaconazole makes it less susceptible to be affected by mutations in the enzyme resulting in resistance of fungi (formularyjournal.com). | The primary component of Noxafil, posaconazole (green link) is a potent, broad-spectrum antifungal drug. It was derived from a similar triazole antifungal agent, Itraconazole. The differences in structure are that the chlorine substituents in the aromatic ring on the left-hand side of the images are replaces with fluorines (green link) and that the triazolone sidechain is hydroxylated in the posaconazole structure<ref>PMID: 21059682 </ref>. The extended side chain residues and hydrophobic contacts enhances antifungal activity by allowing tighter binding affinities to the <scene name='75/756730/Hemegroup/1'>heme cofactor</scene> in the active site of CYP450-dependent enzyme lanosterol alpha-demthylase (CYP51) (Groll)(academic.oup.com). The tighter binding affinity of posaconazole makes it less susceptible to be affected by mutations in the enzyme resulting in resistance of fungi (formularyjournal.com). | ||
(explanation of green links/figures?) | (explanation of green links/figures?) | ||
